Paul Alloway - 25 Mar 2024 Form 4 Insider Report for Q32 Bio Inc. (QTTB)

Reporting relationship: Former President and Chief Operating Officer of Homology Medicines, Inc.
Issuer ticker: QTTB
Reported as of: 25 Mar 2024
Net transaction value: -$6,488
SEC form: 4
Accepted by SEC: 23 Apr 2024, 17:03:07 UTC
Prior SEC filing: 05 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Paul Alloway

Key filing fact

Paul Alloway filed Form 4 for Q32 Bio Inc. (QTTB) on 23 Apr 2024.

Key facts

This page summarizes Paul Alloway's Form 4 filing for Q32 Bio Inc. (QTTB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Apr 2024, 17:03.

Change

Previous filing in this sequence was filed on 05 Jan 2024.
Current net transaction value: -$6,488.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

QTTB transaction

Common Stock

Sale

Transaction value: $6,488
Shares: -268
Change %: -9.4%
Price: $24.21^*
Shares after: 2,596
Date: 25 Mar 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Paul Alloway is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of the RSUs.

Footnote F2

On March 25, 2024, the Issuer effected a 1-for-18 reverse stock split (the "Reverse Stock Split"). The share counts herein have been adjusted to reflect the Reverse Stock Split.

SEC remarks

Former President and Chief Operating Officer of Homology Medicines, Inc.